| ²é¿´: 1330 | »Ø¸´: 4 | |||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | |||
laberleeľ³æ (СÓÐÃûÆø)
|
[½»Á÷]
¡¾ÇóÖú¡¿ÇóÓйذ¢´ïľµ¥¿¹µÄ·¢ÏÖ¡¢ÁÙ´²Ç°Ñо¿¡¢ÁÙ´²Ñо¿£¬FDAÉêÇ룬¼¼Êõ×ªÒÆµÄÓйØÎÄÏÒÑÓÐ3È˲ÎÓë
|
||
ÏÈллÁË¡£¡£ÎÒʵÔÚËѲ»µ½ |
» ²ÂÄãϲ»¶
ÎÄÏ×ÇóÖú
ÒѾÓÐ1È˻ظ´
ÈçºÎ¸ßЧµÄ²âÁ¿ÏÙ²¡¶¾µÄÁ£¾¶ºÍµçλ
ÒѾÓÐ0È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ91È˻ظ´
26ÔÚÖ°É격¡ªÉúÎïÓëÒ½Ò©¡ª¿¹Ìå/ADCÒ©Îï·½Ïò£¬½Õ㻦£¬ÓÐÏîÄ¿£¬¿É´ø×Ê¡£
ÒѾÓÐ1È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
¸÷λÆÀί£¬¶ÔǧÈË£¬³¤½£¬½ÜÇàºÍÎÞÃûС×äÉêÇëÃæÉÏÏîÄ¿£¬ÓÐʲôȡÉáÆ«ºÃÂð£¿
ÒѾÓÐ12È˻ظ´
ÇóÖúÒ»¸ö¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðÕªÒª£¡£¡ÐèÒª¶£µ±±Ò
ÒѾÓÐ3È˻ظ´
ÓÐÈËÓöµ½¹ýÒòΪ¡°²»ÊôÓÚ±¾Ñ§¿Æ×ÊÖú·¶³ë¡±¶ø²»ÓèÊÜÀíµÄ¹ú¼Ò»ù½ðÉêÇëÂð£¿
ÒѾÓÐ15È˻ظ´
15·Ý¹ú»ù£¬6·ÝÇàÄ꣬9·ÝÃæÉÏ£¬È«²¿´òÓ¡³öÀ´£¡
ÒѾÓÐ20È˻ظ´
¹ØÓÚ½ðÊôºÍºÏ½ð²ã´íÄÜÏà¹ØµÄÑо¿ÎÄÏ×
ÒѾÓÐ101È˻ظ´
ÎåÒ»º¯ÆÀ»ù½ðæ
ÒѾÓÐ25È˻ظ´
Õâ¸öÊÀ½çÕæÊÇÂÒÁË£¬ÓеÄÒªÇóÀÏ°å±ØÐëÓеÚÒ»×÷Õߣ¬ÓеÄ×î·³ÀϰåÓеÚÒ»×÷Õߣ¬ÄãÃÇÊÇÆÀ
ÒѾÓÐ12È˻ظ´
·°ËáÑÎÌåϵµÄ°×¹âLEDÑо¿ÓÐʲôÓÅÊÆ»òÕߺô¦
ÒѾÓÐ4È˻ظ´
ÆÕͨÈËÕæµÄ²»ÄÜ£³ÏîͬʱÔÚÊÖ£¿
ÒѾÓÐ16È˻ظ´
°ïÅóÓÑÎÊһϷÖÎö»¯Ñ§µÄÊÇ·ñ¿ÉÒÔ¿¼ÁÙ´²¼ìÑéÕï¶Ïѧ£¿
ÒѾÓÐ4È˻ظ´
hardee
Ìú¸Ëľ³æ (ÖªÃû×÷¼Ò)
´Ë²ÝÓÐÖ÷~
- DRDEPI: 12
- Ó¦Öú: 152 (¸ßÖÐÉú)
- ¹ó±ö: 0.03
- ½ð±Ò: 10928.3
- É¢½ð: 5544
- ºì»¨: 49
- ɳ·¢: 40
- Ìû×Ó: 6865
- ÔÚÏß: 2905.6Сʱ
- ³æºÅ: 891544
- ×¢²á: 2009-11-02
- ÐÔ±ð: GG
- רҵ: Ò©Îﻯѧ
¡ï ¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
chinarencxp(½ð±Ò+1): ¹ÄÀø»ý¼«½»Á÷ 2011-04-16 22:20:18
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
chinarencxp(½ð±Ò+1): ¹ÄÀø»ý¼«½»Á÷ 2011-04-16 22:20:18
|
Ëæ±ã¿´¿´°É£º Title: Adalimumab CAS Registry Number: 331731-18-1 CAS Name: Anti-(human tumor necrosis factor) immunoglobulin G1 (human monoclonal D2E7 heavy chain) disulfide with human monoclonal D2E7 light chain, dimer Manufacturers' Codes: D2E7 Trademarks: Humira (Abbott) Literature References: Fully human monoclonal antibody against tumor necrosis factor a (TNFa). Prepn: J. G. Salfeld et al., WO 9729131; eidem, US 6090382 (1997, 2000 both to BASF). Characterization: L. C. Santora et al., Anal. Biochem. 275, 98 (1999). Characterization of antigen binding: idem et al., ibid. 299, 119 (2001). Clinical trial in rheumatoid arthritis: A. A. den Broeder et al., Ann. Rheum. Dis. 61, 311 (2002); in combination with methotrexate: F. C. Breedveld et al., Arthritis Rheum. 54, 26 (2006); in psoriatic arthritis: P. J. Mease et al., ibid. 52, 3279 (2005). Review of pharmacology and clinical experience: K. P. Machold, J. S. Smolen, Expert Opin. Biol. Ther. 3, 351-360 (2003). Review of safety and efficacy in psoriasis and rheumatoid arthritis: T. Patel, K. B. Gordon, Dermatol. Ther. 17, 427-431 (2004); in psoriatic arthritis: P. J. Mease, Expert Opin. Biol. Ther. 5, 1491-1504 (2005). Therap-Cat: Anti-inflammatory. Keywords: Anti-inflammatory (Biological Response Modifier). |

3Â¥2011-04-16 08:36:54
laberlee
ľ³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 2133.7
- Ìû×Ó: 57
- ÔÚÏß: 58.6Сʱ
- ³æºÅ: 1230959
- ×¢²á: 2011-03-12
- ÐÔ±ð: MM
- רҵ: ÄÜÔ´»¯¹¤
4Â¥2011-04-18 15:46:47
Ò©µÀÈË
ÈÙÓþ°æÖ÷ (ÎÄ̳¾«Ó¢)
¾»ÓÉ»àÉú£¬Ã÷´Ó霳ö
-

ר¼Ò¾Ñé: +71 - DRDEPI: 1
- Ó¦Öú: 38 (СѧÉú)
- ¹ó±ö: 6.92
- ½ð±Ò: 27026.1
- É¢½ð: 9994
- ºì»¨: 143
- ɳ·¢: 178
- Ìû×Ó: 25008
- ÔÚÏß: 1356.1Сʱ
- ³æºÅ: 336426
- ×¢²á: 2007-04-01
- ÐÔ±ð: GG
- רҵ: µÀ½Ì
- ¹ÜϽ: ½ðÈÚͶ×Ê

5Â¥2011-06-16 13:27:36













ÏÈллÁË¡£¡£ÎÒʵÔÚËѲ»µ½
»Ø¸´´ËÂ¥

ÄãÊÇʲô¹«Ë¾°¡